Diamyd Medical AB
– Fighting diabetes
Diamyd Medical is a company dedicated to the fight against diabetes. The diabetes vaccine Diamyd® is the company’s furthest developed drug candidate. It has the potential to become a key piece of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes that includes both type 1 diabetes and latent autoimmune diabetes in the adult (LADA).
The diabetes vaccine Diamyd® is considered to be the world’s furthest developed Antigen Based Therapy (ABT) for treating the disease.
Type 1 diabetes and LADA
Type 1 diabetes and LADA are autoimmune forms of diabetes, meaning that the body’s own immune system destroys the beta cells in the body that produce insulin and regulate blood sugar. Patients with fully developed type 1 diabetes and LADA depend upon daily insulin injections for their survival. But insulin does not address the underlying disease process and even well controlled patients suffer from severe diabetes complications.
The diabetes vaccine Diamyd®
The diabetes vaccine Diamyd® is aimed to prevent, stop or delay the autoimmune process and preserve the body’s own ability to produce insulin in type 1 diabetes and LADA. Large studies show that preservation of at least some of the insulin-producing capacity reduces diabetes complications by 60 to 80%. In a European Phase III study Diamyd® showed good clinical effect in several subgroups, and a limited overall 16% efficacy (p=0.10) in preserving endogenous insulin secretion. To enhance the overall effect, combination treatments with Diamyd® and other approved agents are being pursued. Diamyd® has been used in clinical studies with more than 1,000 patients, has shown a good safety profile and is easy to administer in any clinical setting.
With 80,000 new patients per year in Europe and the US the potential annual market is estimated to several billion dollars. Diamyd Medical exclusively licenses UCLA-rights to GAD65, the active ingredient in the vaccine, for which the last patent expires in 2032. Additionally, the company exclusively licenses UCLA patents for using GABA for the treatment of diabetes and other inflammation-related conditions.
Ongoing Clinical Trials
Ongoing development work is aimed at enhancing the efficacy of the treatment by combining Diamyd® with other agents and to treat earlier in the disease process. New approaches are being evaluated in several clinical studies together with different teams of researchers. Six researcher-initiated clinical studies with Diamyd® are ongoing in Sweden and US.
Diamyd Medical is looking to enter alliances with industrial partners for the further development and commercialization of the diabetes vaccine Diamyd® as well as GABA. The company has expertise and a global network within diabetes and is actively looking for opportunities to expand in the diabetes area. Both new development projects and fully developed diabetes products and companies are of interest. The Diamyd Medical share is listed on the NASDAQ Stockholm First North list (ticker: DMYD B).